Haemonetics Corp (HAE, Financial) files its latest 10-K with SEC for the fiscal year ended on March 31, 2018. Haemonetics Corp is a health care company. It provides products enabling the processing, handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes. Haemonetics Corp has a market cap of $4.85 billion; its shares were traded at around $90.77 with a P/E ratio of 105.53 and P/S ratio of 5.31. Haemonetics Corp had annual average EBITDA growth of 1.80% over the past ten years.
For the last quarter Haemonetics Corp reported a revenue of $233.6 million, compared with the revenue of $228.1 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $903.9 million, an increase of 2% from last year. For the last five years Haemonetics Corp had an average revenue decline of 0.3% a year.
The reported diluted earnings per share was 85 cents for the year. The Haemonetics Corp had an operating margin of 6.21%, compared with the operating margin of 4.43% a year before. The 10-year historical median operating margin of Haemonetics Corp is 6.51%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Haemonetics Corp has the cash and cash equivalents of $180.2 million, compared with $139.6 million in the previous year. The long term debt was $59.4 million, compared with $253.6 million in the previous year. Haemonetics Corp has a financial strength rank of 7 (out of 10).
At the current stock price of $90.77, Haemonetics Corp is traded at 128.6% premium to its historical median P/S valuation band of $39.71. The P/S ratio of the stock is 5.31, while the historical median P/S ratio is 2.34. The stock gained 121.38% during the past 12 months.
For the complete 20-year historical financial data of HAE, click here.
